ADXSHER-2 is under clinical development by OS Therapies and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADXSHER-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADXSHER-2 overview

ADXS-HER2 (OST-HER2) is under development for the treatment of pediatric osteosarcoma. It is a HER-2/neu vaccine targets internal and external sites on the HER-2 antigen associated with aggressive breast cancer. It is developed based on Listeria technology platform. It was also under development for the treatment of HER2 expressing cancers such as metastatic breast cancer, esophageal cancer and gastric cancer.

OS Therapies overview

OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for Osteosarcoma. The company is headquartered in Fairfax, Virginia, the US

For a complete picture of ADXSHER-2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.